| Literature DB >> 33718306 |
Elpis Hatziagorou1, Asterios Kampouras1, Vasiliki Avramidou1, Ilektra Toulia1, Elisavet-Anna Chrysochoou1, Maria Galogavrou1, Fotios Kirvassilis1, John Tsanakas1.
Abstract
As Cystic Fibrosis (CF) treatment advances, research evidence has highlighted the value and applicability of Lung Clearance Index and Cardiopulmonary Exercise Testing as endpoints for clinical trials. In the context of these new endpoints for CF trials, we have explored the use of these two test outcomes for routine CF care. In this review we have presented the use of these methods in assessing disease severity, disease progression, and the efficacy of new interventions with considerations for future research.Entities:
Keywords: cardiopulmonary exercise testing (CPET); cystic fibrosis; disease progression; disease severity; endpoints; lung clearance index (LCI)
Year: 2021 PMID: 33718306 PMCID: PMC7946844 DOI: 10.3389/fped.2021.635719
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418